AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30018101 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 1008
Study 26857054 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 312
Study 26857054 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 312
Study 24200335 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - participated in a physical conditioning program throughout pregnancy, 55-60 minutes, 3 days per week
Number of subjects: 200
Study 24200335 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - no exercise program
Number of subjects: 200
Study 24367946 — intervention group
Group type: EXPERIMENTAL
Intervention: PALM (formula containing palm olein, palm kernel oil, and canola oil)
Number of subjects: 33
Study 24367946 — intervention group
Group type: COMPARATOR
Intervention: NoPALM (formula without palm olein, palm kernel oil, and canola oil)
Number of subjects: 33
Study 20487046 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (dutasteride 0.5 mg + tamsulosin 0.4 mg)
Number of subjects: 4844
Study 20487046 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg
Number of subjects: 4844
Study 20487046 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 4844
Study 20487046 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (dutasteride + tamsulosin)
Number of subjects: 4844
Study 17935974 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (Rit) as a single agent
Number of subjects: 0
Study 17935974 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (Rit) in combination with chemotherapy
Number of subjects: 0
Study 17935974 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of Rituximab to standard chemotherapy
Number of subjects: 0
Study 16632079 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 344
Study 16632079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study 14660152 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine users (women) reporting abuse or violence from a partner
Number of subjects: 1016
Study 14660152 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine users (men) reporting violence from friends and others
Number of subjects: 1016
Study 14660152 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine users reporting threatening or coercive experiences with partners
Number of subjects: 1016
Study 14660152 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine users entering treatment for methamphetamine dependence
Number of subjects: 1016
Study 15471834 — intervention group
Group type: COMPARATOR
Intervention: 123I‐FP‐CIT binding (normal)
Number of subjects: 20
Study 15471834 — intervention group
Group type: COMPARATOR
Intervention: 123I‐FP‐CIT binding (abnormal)
Number of subjects: 20
Study 15471834 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐dopa therapy response (normal scan)
Number of subjects: 20
Study 15471834 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐dopa therapy response (abnormal scan)
Number of subjects: 20
Study 10404476 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MI subjects
Number of subjects: 64
Study 10404476 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 64
Study 10404476 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MI subjects with attentional bias
Number of subjects: 64
Study 7579132 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeblink classical conditioning (EBCC) performed concurrently with tapping
Number of subjects: 140
Study 7579132 — intervention group
Group type: COMPARATOR
Intervention: Eyeblink classical conditioning (EBCC) performed concurrently with a recognition task or control tasks
Number of subjects: 140
Study 2105052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (15 h/d)
Number of subjects: 5
Study 2105052 — intervention group
Group type: COMPARATOR
Intervention: Continuous total parenteral nutrition (24 h/d)
Number of subjects: 5
Study 6998154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 6998154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31652407 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek yogurt (GY) (20 g protein, 208 mg calcium/dose)
Number of subjects: 30
Study 31652407 — intervention group
Group type: COMPARATOR
Intervention: Placebo pudding (PP) (0 g protein, 0 g calcium/dose)
Number of subjects: 30
Study 31652407 — intervention group
Group type: COMPARATOR
Intervention: Placebo pudding (PP)
Number of subjects: 30
Study 31652407 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek yogurt (GY)
Number of subjects: 30
Study 28807073 — intervention group
Group type: EXPERIMENTAL
Intervention: VividTrac VT-A100 (VT)
Number of subjects: 5
Study 28807073 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope Ranger (GL)
Number of subjects: 5
Study 28807073 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 5
Study 28807073 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all devices)
Number of subjects: 5
Study 28807073 — intervention group
Group type: EXPERIMENTAL
Intervention: Average time to successful intubation for VT
Number of subjects: 5
Study 28807073 — intervention group
Group type: EXPERIMENTAL
Intervention: Average time to successful intubation for GL
Number of subjects: 5
Study 28807073 — intervention group
Group type: EXPERIMENTAL
Intervention: Average time to successful intubation for DL
Number of subjects: 5
Study 28807073 — intervention group
Group type: EXPERIMENTAL
Intervention: Average number of intubation attempts for VT
Number of subjects: 5
Study 28807073 — intervention group
Group type: EXPERIMENTAL
Intervention: Average number of intubation attempts for GL
Number of subjects: 5
Study 28807073 — intervention group
Group type: EXPERIMENTAL
Intervention: Average number of intubation attempts for DL
Number of subjects: 5
Study 25840299 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (ketorolac tromethamine 0.5%)
Number of subjects: 2
Study 25840299 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ofloxacin 0.3%)
Number of subjects: 2
Study 24331898 — intervention group
Group type: EXPERIMENTAL
Intervention: OxCAP-MH
Number of subjects: 333
Study 21225277 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days/week ATV
Number of subjects: 58
Study 21225277 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 days/week ORM
Number of subjects: 58
Study 21225277 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days/week ATV
Number of subjects: 58
Study 21225277 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days/week ORM
Number of subjects: 58
Study 21225277 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 19254810 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 382
Study 17353308 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram-synchronized flow-sensitized 4-dimensional MR imaging at 3T
Number of subjects: 0
Study 15476449 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus folic acid (5 mg/day) plus vitamin B12 (500 microg/day) for 1 month
Number of subjects: 50
Study 15476449 — intervention group
Group type: COMPARATOR
Intervention: Diet plus placebo for 2 months
Number of subjects: 50
Study 11503112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed lavage
Number of subjects: 91
Study 11503112 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study 9771301 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled alfentanil infusion
Number of subjects: 120
Study 9771301 — intervention group
Group type: COMPARATOR
Intervention: Morphine PCA
Number of subjects: 120
Study 7877587 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple-preserved mastectomy (Glt+Ax)
Number of subjects: 0
Study 7877587 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 0
Study 3397586 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐methylpyrazole in hydrophilic ointment
Number of subjects: 12
Study 3397586 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic ointment alone
Number of subjects: 12
Study 31730565 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + KME (573 mg·kg of a ketone monoester supplement)
Number of subjects: 8
Study 31730565 — intervention group
Group type: COMPARATOR
Intervention: CHO + PLA (8% carbohydrate-electrolyte solution)
Number of subjects: 8
Study 28107844 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training (90 min per session, 3 days a week for 8 weeks)
Number of subjects: 24
Study 28107844 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 24
Study 26132839 — intervention group
Group type: EXPERIMENTAL
Intervention: Chikungunya virus (CHIKV) IgG antibodies testing
Number of subjects: 1008
Study 26132839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosquito capture and testing
Number of subjects: 1008
Study 21666979 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrients supplementation
Number of subjects: 36
Study 21666979 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert compound)
Number of subjects: 36
Study 19709989 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive credibility cues (trustmarks)
Number of subjects: 85
Study 19709989 — intervention group
Group type: COMPARATOR
Intervention: Negative credibility cues (adverts, pharmaceutical sponsorship, donation button)
Number of subjects: 85
Study 17580727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 0
Study 15121070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt training (35 patients)
Number of subjects: 68
Study 15121070 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls, 33 patients)
Number of subjects: 68
Study 15121070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt training
Number of subjects: 68
Study 12205786 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril and rehydration
Number of subjects: 166
Study 12205786 — intervention group
Group type: COMPARATOR
Intervention: Rehydration alone
Number of subjects: 166
Study 9614617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin (LP)
Number of subjects: 39
Study 9614617 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (ACT)
Number of subjects: 39
Study 9098283 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 41
Study 2559509 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortnightly chemoprophylaxis with Maloprim
Number of subjects: 750
Study 2559509 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving Maloprim)
Number of subjects: 750
Study 845144 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional units for visual imagery training
Number of subjects: 110
Study 845144 — intervention group
Group type: COMPARATOR
Intervention: Control group (no imagery training)
Number of subjects: 110
Study 31694484 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face programming of hearing aids
Number of subjects: 52
Study 31694484 — intervention group
Group type: COMPARATOR
Intervention: Remote programming of hearing aids
Number of subjects: 52
Study 31386217 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pubertal maturation
Number of subjects: 2991
Study 31386217 — intervention group
Group type: COMPARATOR
Intervention: Overweightness and early pubertal maturation
Number of subjects: 2991
Study 31181017 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 0.25 mg/kg with oral rehydration therapy (ORT)
Number of subjects: 292
Study 31181017 — intervention group
Group type: COMPARATOR
Intervention: Placebo with oral rehydration therapy (ORT)
Number of subjects: 292
Study 28591564 — intervention group
Group type: EXPERIMENTAL
Intervention: Model osteoarthritis consultation (MOAC) in intervention practices
Number of subjects: 1960
Study 28591564 — intervention group
Group type: COMPARATOR
Intervention: Usual care in control practices
Number of subjects: 1960
Study 26025570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified (part of a randomized trial)
Number of subjects: 729
Study 23092529 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin hydrochloride
Number of subjects: 124
Study 23092529 — intervention group
Group type: COMPARATOR
Intervention: Polymyxin B‐trimethoprim
Number of subjects: 124
Study 24653477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity therapy plus standard care
Number of subjects: 45
Study 24653477 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 45
Study 19861324 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 4648
Study 19861324 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 4648
Study 16829488 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Response Signal Delay (RSD) group
Number of subjects: 0
Study 16829488 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Response Signal Delay (RSD) group
Number of subjects: 0
Study 16829488 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptual cue generation procedure
Number of subjects: 0
Study 16829488 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagram generation procedure
Number of subjects: 0
Study 16829488 — intervention group
Group type: EXPERIMENTAL
Intervention: 2250-ms RSD
Number of subjects: 0
Study 15283941 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy (estradiol 2 mg/norethisterone acetate 1 mg-Kliogest)
Number of subjects: 80
Study 15283941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 11007080 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 0
Study 11007080 — intervention group
Group type: COMPARATOR
Intervention: Standard tracheostomy (ST)
Number of subjects: 0
Study 9068313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 5
Study 9068313 — intervention group
Group type: COMPARATOR
Intervention: Historical group (control)
Number of subjects: 5
Study 9068313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 5
Study 8313746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylestriol 2 mg/2 weeks (Group A)
Number of subjects: 283
Study 8313746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylestriol 1 mg/2 weeks (Group B)
Number of subjects: 283
Study 8313746 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 283
Study 3525424 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 21
Study 3525424 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg)
Number of subjects: 21
Study 31077891 — intervention group
Group type: EXPERIMENTAL
Intervention: Biportal endoscopic lumbar decompressive laminectomy (BE‐D)
Number of subjects: 64
Study 31077891 — intervention group
Group type: COMPARATOR
Intervention: Mini-open microscopic lumbar decompressive laminectomy (MI‐D)
Number of subjects: 64
Study 29031768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation therapy (100% oxygen in hyperbaric conditions)
Number of subjects: 109
Study 29031768 — intervention group
Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 109
Study 27480410 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte A (PLA)
Number of subjects: 100
Study 27480410 — intervention group
Group type: COMPARATOR
Intervention: 0.9 % sodium chloride (NaCl)
Number of subjects: 100
Study 24667749 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% alginate CM
Number of subjects: 24
Study 24667749 — intervention group
Group type: COMPARATOR
Intervention: 1.25% alginate CM
Number of subjects: 24
Study 22757595 — intervention group
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training (RT)
Number of subjects: 38
Study 22757595 — intervention group
Group type: COMPARATOR
Intervention: Diversionary Activities (DA)
Number of subjects: 38
Study 20399113 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral femoral puncture
Number of subjects: 57
Study 20399113 — intervention group
Group type: COMPARATOR
Intervention: Unilateral femoral puncture
Number of subjects: 57
Study 18942274 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced decision aid
Number of subjects: 87
Study 18942274 — intervention group
Group type: COMPARATOR
Intervention: Usual care decision aid
Number of subjects: 87
Study 15230823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 30
Study 15230823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11824669 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg the evening before and 40 mg the morning of surgery)
Number of subjects: 20
Study 11824669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 20
Study 9572206 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls from registered nurses, one or two times weekly from 24 weeks' through 37 weeks' gestation
Number of subjects: 1554
Study 9572206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1554
Study 9572206 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls from registered nurses, one or two times weekly from 24 weeks' through 37 weeks' gestation in low-income black women 19 years of age and older
Number of subjects: 1554
Study 9572206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention) in low-income black women 19 years of age and older
Number of subjects: 1554
Study 8068791 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning letters threatening prosecution
Number of subjects: 255
Study 8068791 — intervention group
Group type: COMPARATOR
Intervention: No warning letters
Number of subjects: 255
Study 2784322 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin A
Number of subjects: 10
Study 2784322 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 57048 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention directed to tones
Number of subjects: 0
Study 57048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone intensity effects on N1 and P2
Number of subjects: 0
Study 57048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined N1-P2 amplitude measures
Number of subjects: 0
Study 57048 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstimulus intervals based on prior intervals
Number of subjects: 0
Study 57048 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to tones
Number of subjects: 0
Study 31745987 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate supplementation
Number of subjects: 51
Study 31745987 — intervention group
Group type: COMPARATOR
Intervention: No potassium citrate supplementation (Control)
Number of subjects: 51
Study 31332045 — intervention group
Group type: EXPERIMENTAL
Intervention: SoC+ECP
Number of subjects: 60
Study 31332045 — intervention group
Group type: COMPARATOR
Intervention: SoC
Number of subjects: 60
Study 27429228 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuka honey applied twice daily
Number of subjects: 55
Study 27429228 — intervention group
Group type: COMPARATOR
Intervention: Control (Vaseline applied 4 times a day)
Number of subjects: 55
Study 27429228 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuka honey
Number of subjects: 55
Study 27429228 — intervention group
Group type: COMPARATOR
Intervention: Control (Vaseline)
Number of subjects: 55
Study 25030325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 67
Study 23072780 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated white blood cell transfusions
Number of subjects: 108
Study 23072780 — intervention group
Group type: EXPERIMENTAL
Intervention: Unirradiated white blood cell transfusions
Number of subjects: 108
Study 21466650 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose tacrolimus with mycophenolate mofetil
Number of subjects: 195
Study 21466650 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose tacrolimus
Number of subjects: 195
Study 17428556 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 17428556 — intervention group
Group type: COMPARATOR
Intervention: Dobutamin
Number of subjects: 0
Study 16701193 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural with bupivacaine 0.1% and fentanyl 3mug/ml
Number of subjects: 27
Study 16701193 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous peripheral nerve block (CPNB) with ropivacaine 0.2%
Number of subjects: 27
Study 16701193 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled analgesia (PCA) with i.v. morphine
Number of subjects: 27
Study 12887380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 122
Study 12887380 — intervention group
Group type: COMPARATOR
Intervention: IRM
Number of subjects: 122
Study 11468003 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Greiff/Grunberg method
Number of subjects: 24
Study 11468003 — intervention group
Group type: COMPARATOR
Intervention: Naclerio method
Number of subjects: 24
Study 9009533 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma primer only (group 1)
Number of subjects: 15
Study 9009533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleanser followed by primer (group 2)
Number of subjects: 15
Study 9009533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleanser followed by primer and sealer (group 3)
Number of subjects: 15
Study 9009533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 15
Study 8289749 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.4 to 0.6%)
Number of subjects: 169
Study 8289749 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.6 to 0.8%)
Number of subjects: 169
Study 8289749 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (0.8 to 1%)
Number of subjects: 169
Study 8289749 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane, Isoflurane, Enflurane
Number of subjects: 169